Clinical trials: High-Risk Cancer, open to volunteers
High Grade Serous Ovarian Cancer, Folate Receptor Alpha Positive
Folate Receptor Alpha (FRα) Expression and Heterogeneity in Epithelial Ovarian Cancer
This is a single-country, retrospective, observational biomarker study conducted in Greece to evaluate Folate Receptor Alpha (FRα) expression in patients with high-grade serous ovarian, fallopian tube, and primary peritoneal…
- Trial name
- FRONTIER (NCT07889843)
- Where
- Greece
- Volunteers
- 200 people
- Sponsor
- Hellenic Cooperative Oncology Group
High Grade Serous Ovarian Cancer
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
The objective of this study is to explore the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cance
- Trial name
- MR-O-MICS (NCT06084195)
- Testing
- Blood sample and tissue sample
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Clear Cell Renal Cell Carcinoma
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
This is a prospective, multicenter, single-arm phase II study evaluating the efficacy and safety of neoadjuvant PD-L1 inhibitor TQB2450 in combination with anlotinib in patients with locally advanced, high-complexity (RENAL score…
- Trial name
- NCT07602101
- Testing
- TQB2450 + Anlotinib
- Volunteers
- 33 people
- Sponsor
- RenJi Hospital
Metastatic Breast Cancer
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
Currently, no phase III RCT has directly compared SG and T-DXd sequencing strategies, and the predictive role of biomarkers remains unclear. Additionally, there is no standard scoring system for Trop-2 expression.
- Trial name
- STORM (NCT07368543)
- Testing
- Sacituzumab Govitecan, Trastuzumab Deruxtecan
- Volunteers
- 216 people
- Sponsor
- Fudan University
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following…
- Conditions
- High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05801913
- Testing
- Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site
Observational Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx and Occult Tumors Positive for Papilloma Virus
Based on the evidence summarized in the introduction, the clinician hypothesize that the detection of the presence and expression of HPV-DNA, certain miRNAs, and a certain mutational profile in the tissues and biological fluids…
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, Carcinomas of Unknown Primary Site, High-risk Human Papillomavirus Infection, Liquid Biopsy
- Trial name
- NCT05918510
- Testing
- Study of Viral BIOmarkers and microRNAs in Tumors Orofarynx
- Where
- Italy
- Volunteers
- 142 people
- Sponsor
- Regina Elena Cancer Institute
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT06440850
- Testing
- Biospecimen Collection, Cobimetinib, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Nasopharyngeal Carcinoma
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II…
- Trial name
- NCT06851247
- Testing
- Toripalimab, Anlotinib, Gemcitabine
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Cervical Intraepithelial Neoplasia-II, High Risk Human Papillomavirus
Effect of Honey For CIN II
The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.
- Trial name
- HoneyForCINII (NCT06219018)
- Testing
- Medical grade honey formulation (MGH) (L-Mesitran®)
- Where
- 2 sites in Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zuyderland Medisch Centrum
Multiple Myeloma, Carfilzomib
The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients
This study is a prospective, single center, single arm phase II clinical trial. The study population consists of patients who have received treatment with VRd or VRd lite regimens for 2-8 courses in the past and have achieved…
- Conditions
- Multiple Myeloma, Carfilzomib, Daratumumab, Pomalidomide
- Trial name
- DKPD (NCT07015021)
- Testing
- Daratumumab, Cafizomide, Pomalidomide
- Volunteers
- 72 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma (DLBCL)
Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response
This is a prospective, single-arm, single-center clinical study evaluating pomalidomide combined with rituximab as maintenance treatment in young high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who…
- Trial name
- NCT07760610
- Testing
- Pomalidomide, Rituximab
- Volunteers
- 27 people
- Sponsor
- The First Hospital of Jilin University
Lymphoma
Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
To develop a novel method for evaluating treatment response in lymphoma by utilizing PET/CT imaging data from patients with high-metabolic lymphoma.
- Trial name
- NCT06795113
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Ruijin Hospital
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Metastatic Breast Cancer
Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)
This study is a prospective observational study on outcomes of high precision hypo-fractionated radiotherapy in breast cancer with distant metastasis.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Radiation Therapy Complication
- Trial name
- NCT05907681
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias
Screening Women With Prior HPV for Anal Neoplasia
The goal of this single arm trial is to prospectively evaluate screening methods for anal cancer precursors in HIV uninfected women with a history of lower genital tract neoplasias and cancers.
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Trial name
- SWAN (NCT05217940)
- Testing
- Diagnostic tests for anal cancer screening
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Lung Cancer, Nonsmall Cell
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.
- Trial name
- NCT06319950
- Testing
- Furmonertinib, Osimertinib
- Volunteers
- 255 people
- Sponsor
- Taizhou Hospital
Ovarian Neoplasms, Endometrial Neoplasms
DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer
- Trial name
- DOvEEgene (NCT02288676)
- Where
- Canada
- Volunteers
- 1,200 people
- Sponsor
- McGill University
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Cancer, Metastatic Cancer
Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy
This phase 1 clinical trial aims to evaluate the safety, tolerability and feasibility of combination treatment of High Intensity Focused Ultrasound Histotripsy (HIFU-HT) and immune checkpoint inhibitors (ICI) in adult patients…
- Trial name
- iFOCUS (NCT06524570)
- Testing
- HIFU-HT, ICI
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- UMC Utrecht
Platinum-resistant Ovarian Cancer
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
This is phase 2 single arm study evaluating the safety and preliminary efficacy of M-CENK adoptive cell therapy and fixed dose of N-803 in combination with gemcitabine in participants with platinum-resistant high-grade ovarian…
- Trial name
- NCT06710288
- Testing
- Gemcitabine, N-803, M-CENK
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.